Chronic Myeloid Leukemia, Version 2.2024

Neil P. Shah; Ravi Bhatia; Jessica K. Altman; Maria Amaya; Kebede H. Begna; Ellin Berman; Onyee Chan; Joan Clements; Robert H. Collins; Peter T. Curtin; Daniel J. DeAngelo; Michael Drazer; Lori Maness; Leland Metheny; Sanjay Mohan; Joseph O. Moore; Vivian Oehler; Keith Pratz; Iskra Pusic; Michal G. Rose; William Shomali; B. Douglas Smith; Michael Styler; Moshe Talpaz; Tiffany N. Tanaka; Srinivas Tantravahi; James Thompson; Steven Tsai; Jennifer Vaughn; Jeanna Welborn; David T. Yang; Hema Sundar; Kristina Gregory

doi:10.6004/jnccn.2024.0007

Chronic Myeloid Leukemia, Version 2.2024

Neil P. Shah, Ravi Bhatia, Jessica K. Altman, Maria Amaya, Kebede H. Begna, Ellin Berman, Onyee Chan, Joan Clements, Robert H. Collins, Peter T. Curtin, Daniel J. DeAngelo, Michael Drazer, Lori Maness, Leland Metheny, Sanjay Mohan, Joseph O. Moore, Vivian Oehler, Keith Pratz, Iskra Pusic, Michal G. RoseWilliam Shomali, B. Douglas Smith, Michael Styler, Moshe Talpaz, Tiffany N. Tanaka, Srinivas Tantravahi, James Thompson, Steven Tsai, Jennifer Vaughn, Jeanna Welborn, David T. Yang, Hema Sundar, Kristina Gregory

Hematology

Research output: Contribution to journal › Article › peer-review

Abstract

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome resulting from a reciprocal translocation between chromosomes 9 and 22 [t9;22] that gives rise to a BCR::ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase in developed countries. Tyrosine kinase inhibitor (TKI) therapy is a highly effective treatment option for patients with chronic phase-CML. The primary goal of TKI therapy in patients with chronic phase-CML is to prevent disease progression to accelerated phase-CML or blast phase-CML. Discontinuation of TKI therapy with careful monitoring is feasible in selected patients. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with chronic phase-CML.

Original language	English (US)
Pages (from-to)	43-69
Number of pages	27
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	22
Issue number	1
DOIs	https://doi.org/10.6004/jnccn.2024.0007
State	Published - Feb 2024

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2024.0007

Cite this

Shah, N. P., Bhatia, R., Altman, J. K., Amaya, M., Begna, K. H., Berman, E., Chan, O., Clements, J., Collins, R. H., Curtin, P. T., DeAngelo, D. J., Drazer, M., Maness, L., Metheny, L., Mohan, S., Moore, J. O., Oehler, V., Pratz, K., Pusic, I., ... Gregory, K. (2024). Chronic Myeloid Leukemia, Version 2.2024. JNCCN Journal of the National Comprehensive Cancer Network, 22(1), 43-69. https://doi.org/10.6004/jnccn.2024.0007

Shah, NP, Bhatia, R, Altman, JK, Amaya, M, Begna, KH, Berman, E, Chan, O, Clements, J, Collins, RH, Curtin, PT, DeAngelo, DJ, Drazer, M, Maness, L, Metheny, L, Mohan, S, Moore, JO, Oehler, V, Pratz, K, Pusic, I, Rose, MG, Shomali, W, Douglas Smith, B, Styler, M, Talpaz, M, Tanaka, TN, Tantravahi, S, Thompson, J, Tsai, S, Vaughn, J, Welborn, J, Yang, DT, Sundar, H & Gregory, K 2024, 'Chronic Myeloid Leukemia, Version 2.2024', JNCCN Journal of the National Comprehensive Cancer Network, vol. 22, no. 1, pp. 43-69. https://doi.org/10.6004/jnccn.2024.0007

@article{8bef67b2a8314df2b670e272b23b88d3,

title = "Chronic Myeloid Leukemia, Version 2.2024",

abstract = "Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome resulting from a reciprocal translocation between chromosomes 9 and 22 [t9;22] that gives rise to a BCR::ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase in developed countries. Tyrosine kinase inhibitor (TKI) therapy is a highly effective treatment option for patients with chronic phase-CML. The primary goal of TKI therapy in patients with chronic phase-CML is to prevent disease progression to accelerated phase-CML or blast phase-CML. Discontinuation of TKI therapy with careful monitoring is feasible in selected patients. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with chronic phase-CML.",

author = "Shah, {Neil P.} and Ravi Bhatia and Altman, {Jessica K.} and Maria Amaya and Begna, {Kebede H.} and Ellin Berman and Onyee Chan and Joan Clements and Collins, {Robert H.} and Curtin, {Peter T.} and DeAngelo, {Daniel J.} and Michael Drazer and Lori Maness and Leland Metheny and Sanjay Mohan and Moore, {Joseph O.} and Vivian Oehler and Keith Pratz and Iskra Pusic and Rose, {Michal G.} and William Shomali and {Douglas Smith}, B. and Michael Styler and Moshe Talpaz and Tanaka, {Tiffany N.} and Srinivas Tantravahi and James Thompson and Steven Tsai and Jennifer Vaughn and Jeanna Welborn and Yang, {David T.} and Hema Sundar and Kristina Gregory",

year = "2024",

month = feb,

doi = "10.6004/jnccn.2024.0007",

language = "English (US)",

volume = "22",

pages = "43--69",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "1",

}

TY - JOUR

T1 - Chronic Myeloid Leukemia, Version 2.2024

AU - Shah, Neil P.

AU - Bhatia, Ravi

AU - Altman, Jessica K.

AU - Amaya, Maria

AU - Begna, Kebede H.

AU - Berman, Ellin

AU - Chan, Onyee

AU - Clements, Joan

AU - Collins, Robert H.

AU - Curtin, Peter T.

AU - DeAngelo, Daniel J.

AU - Drazer, Michael

AU - Maness, Lori

AU - Metheny, Leland

AU - Mohan, Sanjay

AU - Moore, Joseph O.

AU - Oehler, Vivian

AU - Pratz, Keith

AU - Pusic, Iskra

AU - Rose, Michal G.

AU - Shomali, William

AU - Douglas Smith, B.

AU - Styler, Michael

AU - Talpaz, Moshe

AU - Tanaka, Tiffany N.

AU - Tantravahi, Srinivas

AU - Thompson, James

AU - Tsai, Steven

AU - Vaughn, Jennifer

AU - Welborn, Jeanna

AU - Yang, David T.

AU - Sundar, Hema

AU - Gregory, Kristina

PY - 2024/2

Y1 - 2024/2

N2 - Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome resulting from a reciprocal translocation between chromosomes 9 and 22 [t9;22] that gives rise to a BCR::ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase in developed countries. Tyrosine kinase inhibitor (TKI) therapy is a highly effective treatment option for patients with chronic phase-CML. The primary goal of TKI therapy in patients with chronic phase-CML is to prevent disease progression to accelerated phase-CML or blast phase-CML. Discontinuation of TKI therapy with careful monitoring is feasible in selected patients. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with chronic phase-CML.

AB - Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome resulting from a reciprocal translocation between chromosomes 9 and 22 [t9;22] that gives rise to a BCR::ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase in developed countries. Tyrosine kinase inhibitor (TKI) therapy is a highly effective treatment option for patients with chronic phase-CML. The primary goal of TKI therapy in patients with chronic phase-CML is to prevent disease progression to accelerated phase-CML or blast phase-CML. Discontinuation of TKI therapy with careful monitoring is feasible in selected patients. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with chronic phase-CML.

UR - http://www.scopus.com/inward/record.url?scp=85185866114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85185866114&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2024.0007

DO - 10.6004/jnccn.2024.0007

M3 - Article

C2 - 38394770

AN - SCOPUS:85185866114

SN - 1540-1405

VL - 22

SP - 43

EP - 69

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 1

ER -

Chronic Myeloid Leukemia, Version 2.2024

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this